Ovarian cancer progression is controlled by phenotypic changes in dendritic cells

Dendritic cells are transformed to become immunosuppressive during ovarian cancer progression.

• Publication year

  2012

• Venue

  Journal of Experimental Medicine

• Publication date

  2012-03-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/jem.20111413PMID 22351930PMCID 3302234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011influential reference
• Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

  2011cited by this paper
• Antigen-Presenting Cell (APC) Subsets in Ovarian Cancer

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Myeloid-Derived Suppressor Cells in Human Cancer

  2010cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.

  2009influential reference
• Cancer Statistics, 2009

  2009influential reference
• A role for BRCA1 in uterine leiomyosarcoma.

  2009cited by this paper
• A Role for BRCA 1 in Uterine Leiomyosarcoma

  2009cited by this paper
• Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

  2008influential reference
• PILAR is a novel modulator of human T-cell expansion.

  2008cited by this paper
• Adaptive immunity maintains occult cancer in an equilibrium state

  2007cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

  2007cited by this paper
• Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

  2007cited by this paper
• Classification of Cancer Cell Lines Using an Automated Two-dimensional Liquid Mapping Method with Hierarchical Clustering Techniques*

  2006cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• Dendritic cells maximize the memory CD8 T cell response to infection.

  2005cited by this paper
• Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer

  2005cited by this paper
• Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.

  2003cited by this paper
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.

  2003influential reference
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.

  2002cited by this paper
• Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer

  2001cited by this paper
• Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

  2001cited by this paper
• Cancer statistics

  1989influential reference
• Open Access Research Article Expression Signatures of Tp53 Mutations in Serous Ovarian Cancers

  year unknowncited by this paper

• Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges

  2026influential citation
• COL11A2 Methylation as a Biomarker for Radiosensitivity and Microenvironment Remodelling in Oral Squamous Cell Carcinoma.

  2026cites this paper
• Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer.

  2025cites this paper
• Tertiary lymphoid structures achieve 'cold' to 'hot' transition by remodeling the cold tumor microenvironment.

  2025cites this paper
• Ovarian Cancer Drives TLR5-Dependent Expansion of Myeloid Progenitors Through Systemic Ligand Dissemination.

  2025cites this paper
• Ovarian Cancer Drives TLR5-Dependent Expansion of Myeloid Progenitors Through Systemic Dissemination of Ligands

  2025cites this paper
• Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications

  2025cites this paper
• Transforming cancer immunotherapy: Overcoming immunosuppression in tumors via gene silencing techniques based on nanoparticles

  2025cites this paper
• TLR5 signaling causes dendritic-cell dysfunction and orchestrates failure of immune checkpoint therapy against ovarian cancer.

  2025cites this paper
• The anti-virus T cell response dominates the anti-cancer response in oncolytic virus therapy

  2025cites this paper
• Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments.

  2025cites this paper
• Insight into the anti-cancer and anti-viral therapeutic properties of biological active molecule prodigiosin

  2025cites this paper
• The brave heart dentritic cells are destroyed by invading cancer cells in ovarian serous tumors

  2025cites this paper
• Immune microenvironment of tumor-draining lymph nodes: insights for immunotherapy

  2025cites this paper
• Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential

  2024cites this paper
• Exosome-mediated Crosstalk in the Tumor Immune Microenvironment: Critical Drivers of Hepatocellular Carcinoma Progression

  2024cites this paper
• Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy

  2024cites this paper
• A Hypoxia-Related miRNA-mRNA Signature for Predicting the Response and Prognosis of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma

  2024cites this paper
• ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway

  2024cites this paper
• Myeloid cell networks determine reinstatement of original immune environments in recurrent ovarian cancer

  2024cites this paper
• MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming.

  2024cites this paper
• The hybrid nanosystem for the identification and magnetic hyperthermia immunotherapy of metastatic sentinel lymph nodes as a multifunctional theranostic agent

  2024cites this paper
• Spatially Resolved in vivo CRISPR Screen Sequencing via Perturb-DBiT

  2024cites this paper
• Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells—Function and Therapeutic Potential

  2024cites this paper
• Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME)

  2024cites this paper
• Transgelin 2 guards T cell lipid metabolism and antitumour function

  2024cites this paper
• Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation.

  2024cites this paper
• Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade

  2024cites this paper
• Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy

  2024cites this paper
• Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma

  2024cites this paper
• Lycium barbarum L. polysaccharide LBP3 exerts the anti-tumor effect through enhancing the function of tumor-associated dendritic cells via inhibiting IRE1α -XBP1 pathway of ER stress

  2024cites this paper
• Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy

  2023cites this paper
• An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer

  2023cites this paper
• New insights into the correlations between circulating tumor cells and target organ metastasis

  2023cites this paper
• FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis

  2023cites this paper
• Targeting the immune microenvironment for ovarian cancer therapy

  2023cites this paper
• Cancer cell-intrinsic mechanisms driving acquired immune tolerance.

  2023cites this paper
• Reactive Oxygen Species-Sensitive Biodegradable Mesoporous Silica Nanoparticles Harboring TheraVac Elicit Tumor-Specific Immunity for Colon Tumor Treatment.

  2023cites this paper
• Transgelin 2 guards T cell lipid metabolic programming and anti-tumor function

  2023cites this paper
• Platelet count and MCHC as independent prognostic markers for feline mammary carcinomas.

  2023cites this paper
• Dendritic cell subsets in cancer immunity and tumor antigen sensing

  2023cites this paper
• Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance

  2023cites this paper
• Exosome regulation of immune response mechanism: Pros and cons in immunotherapy

  2023cites this paper
• Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells

  2023cites this paper
• Methylation across the central dogma in health and diseases: new therapeutic strategies

  2023cites this paper
• Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions

  2022cites this paper
• Chloroquine treatment influences immunologicalmemory through the PD-1/PD-L1 pathway during the initiation of Plasmodium chabaudi infection.

  2022cites this paper
• Rise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer

  2022cites this paper
• Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy

  2022cites this paper
• Cancer Immunology and Immunotherapy: From Defining Basic Immunology to Leading the Fight Against Cancer

  2022cites this paper
• Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy

  2022cites this paper
• Immunometabolism in biofilm infection: lessons from cancer

  2022cites this paper
• Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.

  2022cites this paper
• Prognostic Bone Metastasis-Associated Immune-Related Genes Regulated by Transcription Factors in Mesothelioma

  2022cites this paper
• Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

  2022cites this paper
• Reactivation of dysfunctional dendritic cells by a stress-relieving nanosystem resets anti-tumor immune landscape

  2022cites this paper
• Nuanced role for dendritic cell intrinsic IRE1 RNase in the regulation of antitumor adaptive immunity

  2022cites this paper
• Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

  2022cites this paper
• Lysosomal acid lipase, CSF1R, and PD-L1 determine functions of CD11c+ myeloid-derived suppressor cells

  2022cites this paper
• Estrogen-induced immune changes within the normal mammary gland

  2022cites this paper
• Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells.

  2022cites this paper
• Inflammation and Myeloid Cells in Cancer Progression and Metastasis

  2022cites this paper
• TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures.

  2022cites this paper
• Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets

  2022cites this paper
• Polymeric scaffolds for antitumor immune cell priming

  2022cites this paper
• A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model

  2022cites this paper
• The Role of Indoleamine 2, 3-Dioxygenase 1 in Regulating Tumor Microenvironment

  2022cites this paper
• Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer

  2022influential citation
• Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.

  2022cites this paper
• Polyploid giant cancer cells and ovarian cancer: new insights into mitotic regulators and polyploidy

  2021cites this paper
• The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells

  2021cites this paper
• Molecular insights into phytochemicals-driven break function in tumor microenvironment.

  2021cites this paper
• IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer

  2021cites this paper
• Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies

  2021cites this paper
• Prognostic significance of high circulating sHLA‐G in ovarian carcinoma

  2021cites this paper
• The role of dendritic cells in cancer and anti-tumor immunity.

  2021cites this paper
• Dendritic Cell Vaccines in Ovarian Cancer

  2021cites this paper
• The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy

  2021cites this paper
• CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma.

  2021cites this paper
• Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

  2021cites this paper
• Growth differentiation factor-15 promotes immune escape of ovarian cancer via targeting CD44 in dendritic cells.

  2021cites this paper
• Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment

  2021cites this paper
• Countering the advert effects of lung cancer on the anticancer potential of dendritic cell populations reinstates sensitivity to anti-PD-1 therapy

  2021cites this paper
• The Role of Innate Immune Cells in Tumor Invasion and Metastasis

  2021cites this paper
• Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer

  2021cites this paper
• Tumor-draining lymph nodes: At the crossroads of metastasis and immunity

  2021cites this paper
• The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer

  2021cites this paper
• The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells

  2021cites this paper
• Dendritic Cells as Double-Agents for Breast Tumor Pre-Metastatic Bone Disease Establishment

  2021cites this paper
• Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model

  2021cites this paper
• Heterogeneous Myeloid Cells in Tumors

  2021cites this paper
• Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype

  2020cites this paper
• Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment

  2020cites this paper
• Prognostic utility of preoperative neutrophil-lymphocyte ratio in cats with malignant mammary tumors.

  2020cites this paper
• Development of Novel Small-Molecule Rb Protein Modulator for Ovarian Cancer Immunotherapy

  2020cites this paper
• Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption.

  2020cites this paper
• Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples

  2020cites this paper
• CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.

  2020cites this paper
• PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction

  2020cites this paper
• Shaping of Dendritic Cell Function by the Metabolic Micro-Environment

  2020cites this paper